AChRbeta1 Antibodies

Santa Cruz Biotechnology features a diverse variety of AChRbeta1 monoclonal antibodies for research focused on understanding the acetylcholine receptor beta subunit. AChRbeta1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). AChRbeta1 is a crucial component of the nicotinic acetylcholine receptor, playing an essential role in neurotransmission at the neuromuscular junction. The acetylcholine receptor beta subunit facilitates muscle contraction and has been linked to various neurological disorders, making it a key focus in neurology and pharmacology research. Investigating AChRbeta1 function and regulation can advance therapeutic strategies for conditions such as myasthenia gravis and other neuromuscular diseases. Researchers can explore acetylcholine signaling pathways using specific detection methods with conjugated secondary antibodies, including horseradish peroxidase (HRP), phycoerythrin (PE), and fluorescein isothiocyanate (FITC). Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of neuromuscular junction biology and potential therapeutic applications.